E Milroy1, A Allen. 1. Department of Urology, St. Peter's Hospitals, London, United Kingdom.
Abstract
PURPOSE: We present the long-term results of the first 50 patients treated with a new urethral stent (UroLume) developed in 1985 for recurrent bulbomembranous urethral strictures. MATERIALS AND METHODS: All stents were inserted with the patient under general anesthesia using a standard endoscopic delivery system. Of the patients 27 were followed for 5 years or longer, 5 for 4 years and 18 for shorter periods due to death, illness or other factors. RESULTS: Mean (plus or minus standard deviation) maximum flow rate at last following was 19.7 ml. per second (+/- 6.9), and 93% of the patients were satisfied with the stent. In 8 patients (16%) narrowing developed within the lumen of the stent and in the remaining 84% the stent achieved its purpose of maintaining a good urethral lumen. In 9 patients stricture recurred outside the stent because of inaccurate positioning. All of these complications were satisfactorily treated by an additional overlapping stent. Failures occurred particularly in patients with a long stricture history and extensive periurethral fibrosis. CONCLUSIONS: These results indicate that at 4 to 6 years promising early results with the UroLume stent for urethral strictures are maintained with a low late failure rate. This device is not suitable for all strictures and cases with extensive periurethral fibrosis should be avoided but it remains a useful and successful treatment option for many recurrent bulbomembranous urethral strictures.
PURPOSE: We present the long-term results of the first 50 patients treated with a new urethral stent (UroLume) developed in 1985 for recurrent bulbomembranous urethral strictures. MATERIALS AND METHODS: All stents were inserted with the patient under general anesthesia using a standard endoscopic delivery system. Of the patients 27 were followed for 5 years or longer, 5 for 4 years and 18 for shorter periods due to death, illness or other factors. RESULTS: Mean (plus or minus standard deviation) maximum flow rate at last following was 19.7 ml. per second (+/- 6.9), and 93% of the patients were satisfied with the stent. In 8 patients (16%) narrowing developed within the lumen of the stent and in the remaining 84% the stent achieved its purpose of maintaining a good urethral lumen. In 9 patients stricture recurred outside the stent because of inaccurate positioning. All of these complications were satisfactorily treated by an additional overlapping stent. Failures occurred particularly in patients with a long stricture history and extensive periurethral fibrosis. CONCLUSIONS: These results indicate that at 4 to 6 years promising early results with the UroLume stent for urethral strictures are maintained with a low late failure rate. This device is not suitable for all strictures and cases with extensive periurethral fibrosis should be avoided but it remains a useful and successful treatment option for many recurrent bulbomembranous urethral strictures.
Authors: Melih Culha; Unsal Ozkuvanci; Seyfettin Ciftci; Ali Saribacak; Murat Ustuner; Ufuk Yavuz; Hasan Yilmaz; Levend Ozkan Journal: Int J Clin Exp Med Date: 2014-10-15
Authors: Ibrahim Alnadhari; Nabil N Moohialdin; Venkata Ramana Pai Sampige; Omar Ali; Osama Abdeljaleel; Morshed Salah; Omid Sedigh; Ahmad Shamsodini; Abdulla Al-Ansari Journal: Res Rep Urol Date: 2022-05-12